The ADDF offers funding to researchers in both nonprofit and for-profit organizations. We provide applicants with a streamlined review process—the average time from letter of intent (LOI) decision to award decision is less than four months. For most RFPs, letters of intent are accepted and reviewed on a rolling basis during four cycles each year, corresponding to our four invited full proposal reviews.

In 2016, the letters of intent deadlines for our RFPs follow. (Please note, select co-funded RFPs have separate, annual deadlines.)


Full Proposals Due December 9, 2016


For Clinical Trials for Frontotemporal Degeneration RFP:
Full Proposals Due February 15, 2017

Due by February 17, 2017
Full Proposals Due March 10, 2017

Due by May 19, 2017
Full Proposals Due June 9, 2017

Due by August 18, 2017
Full Proposals Due September 8, 2017

Due by November 17, 2017
Full Proposals Due December 8, 2017

Must be received by 11:59 pm EST on the deadline date.

How to Apply

  1. Carefully review the relevant RFP and the Letter of Intent section in the Academic Proposal Instructions or Biotech Proposal Instructions.
  2. Choose the Academic or Biotech LOI button below, based on the organization through which you’ll be applying. (All nonprofits should apply through the Academic button, and all for-profit companies through Biotech.) Log in or create a new account. On the LOI form, provide Contact Information, Scientific Rationale and Background (max 500 words), Project Deliverables (max 300 words), and Summary of Key Supporting Data (max 300 words). You should receive a response to your LOI within two weeks.
  3. If your LOI is approved by ADDF scientific staff, you will receive an email with a link to submit your Invited Full Proposal. Before you submit, review the Academic Proposal Instructions or Biotech Proposal Instructions. Applicants from biotechnology companies should also review the Program-Related Investments (PRIs) Policy Statement.

The following forms must be submitted as part of your Invited Full Proposal:




Support is provided for personnel costs, supplies (e.g., consumables, chemicals, animals), small non-durable equipment up to $2,500, consultants, and patient costs related to clinical trials. Support is not provided for indirect costs/overhead, capital equipment, equipment service contracts, publication costs, or travel.

Review Process

  • Invited proposals are reviewed externally by members of our Scientific Review Board, which includes scientists from academia and industry with drug discovery expertise. Biotechnology proposals are also reviewed by a member of our Business Review Board.
  • All review Board members sign annual confidential disclosure agreements and must recuse themselves from reviewing any proposals with which they have a conflict of interest.
  • On average, applicants are notified of decisions three months after full proposal submission.
  • Note: Applicants unable to submit the full proposal by the deadline may submit their proposal during the next cycle without submitting a new LOI, unless the proposed work has changed. After two missed deadlines, applicants must submit a new LOI.


  • Please note that applicants may only submit one proposal per cycle, but a single institution may have multiple applicants apply for funding for different projects.
  • Applicants are invited to resubmit proposals up to two times if they are able to address the reviewers' concerns. Resubmissions should include a point-by-point response to the review critiques.



Contact Dan Teng, Grants Associate at or 212.901.7998.

ADDF supports scientific conferences that are relevant to our mission with grants up to $10,000. For more information email us or apply online.


All ADDF Governors, officers, and advisory committee members who participate in the selection of recipients for research grant funding are required to annually complete conflict of interest questionnaires to avoid conflicts of interest and maintain high ethical standards.